Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment

European Journal of Cancer

Volumn 37, Issue 18, 2001, Pages 2373-2378

  Vehmanen, L ^a   Saarto, T ^a   Elomaa, I ^a   Makela P ^a   Valimaki M ^a   Blomqvist, C ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Adjuvant chemotherapy; Amenorrhoea; Biphosphonates; Breast cancer; Clodronate; Postmenopausal osteoporosis

Indexed keywords

BONEFOSR; CLODRONIC ACID; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ADULT; AMENORRHEA; ARTICLE; BONE ATROPHY; BONE DENSITY; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MENSTRUATION; OVARY DISEASE; PREMENOPAUSE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AMENORRHEA; ANTIMETABOLITES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DEMINERALIZATION, PATHOLOGIC; BONE DENSITY; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DENSITOMETRY, X-RAY; FEMALE; FLUOROURACIL; FOLLICLE STIMULATING HORMONE; HUMANS; METHOTREXATE; MIDDLE AGED; OVARIAN DISEASES; PROSPECTIVE STUDIES;

EID: 0035196356     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00317-3     Document Type: Article

References (30)

1. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
2. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer
3. Relative contributions of aging and estrogen deficiency to postmenopausal bone loss
4. Quantitative computed tomography of vertebral spongiosa: A sensitive method for detecting early bone loss after oophorectomy
5. Influence of early age at menopause on vertebral bone mass
6. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients
7. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
8. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
9. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss
10. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy
11. Cyclic clodronate is effective in preventing postmenopausal bone loss: A comparative study with transcutaneous hormone replacement therapy
12. Cyclical intravenous clodronate in postmenopausal osteoporosis: Results of a long-term clinical trial
13. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
14. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
15. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results of the fracture intervention trial
16. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
17. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases
18. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast cancer metastasizing to skeleton
19. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer
20. Palliative pamidronate treatment in patients with bone metastases from breast cancer
21. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate
22. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial
23. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial
24. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
25. Adjuvant clodronate will reduce the incidence of bone metastases in patients with primary operable breast cancer
26. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-Year results of randomized controlled trial
27. Rates of bone loss in the appendicular and axial skeletons of women. Evidence of substantial vertebral bone loss before menopause
28. Rates of change in bone mineral density of the spine, heel, femoral neck and radius in healthy postmenopausal women
29. The effects of menopause on longitudinal bone loss from the spine
30. Effect of menopause on femoral and vertebral bone loss